Use of the Monoclonal Antibody Anti-HER2 Trastuzumab in the Treatment of Metastatic Breast Cancer-Reference-Cited by-同舟云学术

Use of the Monoclonal Antibody Anti-HER2 Trastuzumab in the Treatment of Metastatic Breast Cancer

Published:2008-08 Issue:4 Volume:31 Page:363-368
ISSN:0277-3732
Container-title:American Journal of Clinical Oncology
language:en
Short-container-title:

Author:

Poncet Bénédicte,Bachelot Thomas,Colin Cyrille,Ganne Christell,Jaisson-Hot Isabelle,Orfeuvre Hubert,Peaud Pierre-Yves,Jacquin Jean-Philippe,Salles Bruno,Tigaud Jean-Dominique,Mechin-Cretinon Isabelle,Marechal François,Fournel Cécile,Lenoir Véronique Trillet

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Oncology

Reference14 articles.

1. Human Breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene.;Slamon;Science,1987

2. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.;Vogel;J Clin Oncol,2002

3. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.;Cobleigh;J Clin Oncol,1999

4. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.;Slamon;N Eng J Med,2001

5. Efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: results of a randomized phase II trial by the M77001 Study Group.;Marty;J Clin Oncol,2005

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nanotechnology and Nanomedicine;Fundamentals and Advances in Medical Biotechnology;2022

2. Cost-effectiveness of treatments for HER2-positive metastatic breast cancer and associated metastases: an overview of systematic reviews;Expert Review of Pharmacoeconomics & Outcomes Research;2020-12-01

3. A systematic review of the economic evaluations of trastuzumab in metastatic breast cancer;The Breast Journal;2020-05-07

4. RETRACTED: Cost-utility analysis of trastuzumab combined with Docetaxel for patients with HER-2 positive metastatic breast cancer – real world claim data;Journal of Oncology Pharmacy Practice;2018-01-31

5. A review of the value of human epidermal growth factor receptor 2 (HER2)-targeted therapies in breast cancer;European Journal of Cancer;2018-01